Abstract
Over the past decade, considerable effort was focused on the development of muscarinic and nicotinic agonists for the treatment of Alzheimers disease. The rationale for developing muscarinic agonists was based on the role of acetylcholine in learning and memory function and the consistent neurochemical finding that cholinergic neurons degenerated in Alzheimers patients. Thus far, the clinical utility of muscarinic agonists remains unproven, yet recent studies suggest that muscarinic agonists might be useful in treating not only memory deficits, but also psychiatric disturbances and some of the underlying causes of Alzheimers disease, such as the deposition of Aβ. In addition, nicotinic receptors may play a role in cognitive function and help regulate the toxicity of amyloid precursor protein. Ultimately, cholinergic agonists may prove useful in the treatment of Alzheimers disease.
Keywords: alzheimers disase, cholinergic agonists, muscarinic receptors, talsa cl idine, sabcome line, nicotinic receptors
Current Topics in Medicinal Chemistry
Title: Cholinergic Agonists and the Treatment of Alzheimers Disease
Volume: 2 Issue: 4
Author(s): William S. Messer,Jr.
Affiliation:
Keywords: alzheimers disase, cholinergic agonists, muscarinic receptors, talsa cl idine, sabcome line, nicotinic receptors
Abstract: Over the past decade, considerable effort was focused on the development of muscarinic and nicotinic agonists for the treatment of Alzheimers disease. The rationale for developing muscarinic agonists was based on the role of acetylcholine in learning and memory function and the consistent neurochemical finding that cholinergic neurons degenerated in Alzheimers patients. Thus far, the clinical utility of muscarinic agonists remains unproven, yet recent studies suggest that muscarinic agonists might be useful in treating not only memory deficits, but also psychiatric disturbances and some of the underlying causes of Alzheimers disease, such as the deposition of Aβ. In addition, nicotinic receptors may play a role in cognitive function and help regulate the toxicity of amyloid precursor protein. Ultimately, cholinergic agonists may prove useful in the treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Messer,Jr. S. William, Cholinergic Agonists and the Treatment of Alzheimers Disease, Current Topics in Medicinal Chemistry 2002; 2 (4) . https://dx.doi.org/10.2174/1568026024607553
DOI https://dx.doi.org/10.2174/1568026024607553 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Strategies for the Treatment of Huntingtons Disease
Current Pharmacogenomics Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Renin-Angiotensin-Aldosterone System and Migraine: A Systematic Review of Human Studies
Protein & Peptide Letters Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB
Anti-Cancer Agents in Medicinal Chemistry Visualising Neuroinflammation in Post-Stroke Patients: A Comparative PET Study with the TSPO Molecular Imaging Biomarkers [<sup>11</sup>C]PK11195 and [<sup>11</sup>C]vinpocetine
Current Radiopharmaceuticals Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Neonatal Fever in the Term Infant: Evaluation and Management Strategies
Current Pediatric Reviews Acetylcholinesterase Inhibitors from QSAR Point of View: How Close are We?
Central Nervous System Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Alzheimer Research Pharmacology of Ampakine Modulators: From AMPA Receptors to Synapses and Behavior
Current Drug Targets A Systematic Review of Economic Evaluation Studies of Drug-Based Non-Malignant Chronic Pain Treatment
Current Pharmaceutical Biotechnology Role of Hexokinase and VDAC in Neurological Disorders
Current Molecular Pharmacology Copper Binding Extrinsic to the Octarepeat Region in the Prion Protein
Current Protein & Peptide Science ATP Site-Directed Inhibitors of Protein Kinase CK2: An Update
Current Topics in Medicinal Chemistry Activation of Human Platelets by 2-Arachidonoylglycerol: Role of PKC in NO/cGMP Pathway Modulation
Current Neurovascular Research The Protective Effect of Metformin against Oxandrolone-Induced Infertility in Male Rats
Current Pharmaceutical Design Oxidative Stress Signaling in Alzheimers Disease
Current Alzheimer Research Chemical Properties and Biological Activities of Cyclopentenediones: A Review
Mini-Reviews in Medicinal Chemistry Targeting COVID-19 in Parkinson’s Patients: Drugs Repurposed
Current Medicinal Chemistry Review of Evidence and Perspectives of Flavonoids on Metabolic Syndrome and Neurodegenerative Disease
Protein & Peptide Letters